Opportunity Information: Apply for RFA NS 10 001
Apply for RFA NS 10 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Oct 6, 2009 and posted on Oct 6, 2009.
- Applicants must submit their applications by Dec 10, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $9,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses For profit organizations other than small businesses Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50) opportunity is a National Institutes of Health program run by the National Institute of Neurological Disorders and Stroke (NINDS) to support large, team-based Parkinsons disease (PD) research centers. The central goal is not just to generate new knowledge, but to actively move discoveries along the path toward new treatments. NINDS is inviting both new applications and competing renewals, and it expects to fund about four awards with an estimated total program budget of about 9 million dollars. The award mechanism is a P50 specialized center grant, which is typically used to build coordinated research programs that share infrastructure and are designed to produce outcomes that single-lab projects cannot achieve on their own.
A key feature of this program is the requirement for a genuinely multidisciplinary and integrated center structure. Proposed Udall Centers are expected to combine basic, translational, and clinical research in a coordinated way, and they must be organized around substantial collaboration rather than separate, loosely connected projects. The announcement emphasizes that the Centers goals, as well as the goals of each proposed project, should require collaborative efforts and the use of shared resource cores. In other words, applicants need to show that the Center model is essential to accomplishing the work, and that common cores (shared facilities, services, platforms, or expertise) are necessary for the research to function efficiently and synergistically.
Translation toward therapies is built into the required scientific content. Every proposed Center must include at least one preclinical and/or clinical translational research project. In this announcement, preclinical translation is specifically defined as pre IND/IDE stage research, meaning work that advances potential therapeutic or diagnostic candidates up to the point where an Investigational New Drug application or Investigational Device Exemption could be pursued. Clinical translational projects are described as early-stage studies in human subjects that serve as first steps to turn discoveries from basic science, clinical research, or population studies into new approaches for preventing, treating, or ultimately curing PD. While research on related parkinsonian disorders can be included, it needs to clearly inform or expand the PD research mission rather than drifting away from the primary focus.
From an organizational standpoint, every Center must include an Administrative Core, which is the backbone for leadership, governance, coordination, and management of the overall program. Beyond that, the structure is somewhat flexible within budget limits: applicants can propose additional projects and cores as needed to support their scientific plan. NINDS also encourages, though does not strictly require, a strong clinical presence, such as a clinical translational research project paired with a clinical resource core. In practice, this signals that Centers with strong clinical infrastructure, access to patient populations, standardized clinical assessments, biospecimen handling, and data management capacity may be well positioned, especially if those elements clearly accelerate translation.
The program places heavy emphasis on leadership capacity and institutional commitment. The Udall Center Director (the PI) is expected to be an established scientific leader with visionary leadership skills and a proven track record managing complex research efforts and personnel. The applying institution must also demonstrate real commitment to establishing and sustaining the Center, which generally implies administrative support, protected effort for leadership, space and infrastructure, and a long-term environment where the Center can operate effectively. Successful awardees will not function in isolation: they are expected to participate in a broader network of existing Udall Centers, with the intent of sharing findings, aligning efforts where appropriate, and speeding the movement of new scientific and technological advances into novel PD treatments.
In terms of eligibility, the announcement is broad and includes many organization types, such as public and private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses, and for-profit entities other than small businesses, along with certain other categories. The eligibility information also explicitly includes institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions, among others. There is no cost sharing or matching requirement listed for this opportunity, which reduces barriers for applicants but does not lessen the expectation of strong institutional support and demonstrated capacity.
Administratively, the funding opportunity number is RFA NS 10 001, it was posted October 6, 2009, with an original and current closing date of December 10, 2009, and an archive date of January 10, 2010. The CFDA number associated with the program is 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). Overall, the opportunity is designed for institutions capable of running a coordinated, core-supported research enterprise that unites mechanistic discovery with preclinical and/or early clinical translation, and that can contribute to a national collaborative network aimed at delivering new therapeutic options for people living with Parkinsons disease.
Frequently Asked Questions (FAQs): Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50)
What is the Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50) opportunity?
It is a National Institutes of Health (NIH) program run by the National Institute of Neurological Disorders and Stroke (NINDS) to support large, team-based Parkinsons disease (PD) research centers designed to generate new knowledge and actively move discoveries toward new treatments.
Which NIH institute runs this program?
The program is run by NINDS (National Institute of Neurological Disorders and Stroke).
What is the funding mechanism for this opportunity?
The award uses the P50 specialized center grant mechanism, which is typically used to build coordinated research programs with shared infrastructure and outcomes that single-lab projects generally cannot achieve on their own.
Is NINDS accepting new applications, renewals, or both?
NINDS is inviting both new applications and competing renewals.
How many awards does NINDS expect to make, and what is the estimated total budget?
NINDS expects to fund about four awards, with an estimated total program budget of about 9 million dollars.
What is the central goal of an Udall Center under this opportunity?
The central goal is not only to produce scientific knowledge, but to actively move discoveries along the path toward new treatments for PD.
What kind of center structure does the announcement require?
The program requires a genuinely multidisciplinary and integrated center structure that combines basic, translational, and clinical research in a coordinated way, organized around substantial collaboration rather than separate, loosely connected projects.
What does "integrated" and "collaborative" mean in the context of these Centers?
It means applicants must show that the Center model is essential to accomplishing the proposed work, that projects depend on collaborative efforts, and that shared resource cores (shared facilities, services, platforms, or expertise) are necessary for the research to function efficiently and synergistically.
Are shared resource cores required?
Yes. The announcement emphasizes that Centers should rely on the use of shared resource cores and that the goals of the Center and each project should require collaboration and shared core resources.
What scientific components must every Udall Center include related to translation?
Every proposed Center must include at least one preclinical and/or clinical translational research project.
How does the announcement define preclinical translational research?
Preclinical translation is defined as pre IND/IDE stage research, meaning work that advances potential therapeutic or diagnostic candidates up to the point where an Investigational New Drug (IND) application or Investigational Device Exemption (IDE) could be pursued.
How does the announcement describe clinical translational projects?
Clinical translational projects are described as early-stage studies in human subjects that serve as first steps to turn discoveries from basic science, clinical research, or population studies into new approaches for preventing, treating, or ultimately curing PD.
Can research on related parkinsonian disorders be included?
Yes, research on related parkinsonian disorders can be included, but it needs to clearly inform or expand the PD research mission rather than drifting away from the primary PD focus.
What core is required for every Center?
Every Center must include an Administrative Core, which provides leadership, governance, coordination, and overall management for the program.
Can applicants propose additional projects and cores beyond the Administrative Core?
Yes. Beyond the required Administrative Core, the structure is flexible within budget limits, and applicants can propose additional projects and cores needed to support their scientific plan.
Does NINDS require a strong clinical presence in the Center?
NINDS encourages, though does not strictly require, a strong clinical presence, such as a clinical translational research project paired with a clinical resource core.
What kinds of clinical infrastructure elements are highlighted as potentially valuable?
The announcement signals that clinical infrastructure may position a Center well when it clearly accelerates translation, including access to patient populations, standardized clinical assessments, biospecimen handling, and data management capacity.
What are the expectations for the Udall Center Director (PI)?
The Udall Center Director is expected to be an established scientific leader with visionary leadership skills and a proven track record in managing complex research efforts and personnel.
What is expected from the applicant institution in terms of commitment?
The institution must demonstrate real commitment to establishing and sustaining the Center, generally implying administrative support, protected effort for leadership, space and infrastructure, and a long-term environment for effective Center operations.
Will funded Udall Centers operate independently, or as part of a larger network?
They are expected to participate in a broader network of existing Udall Centers to share findings, align efforts where appropriate, and speed the movement of new scientific and technological advances into novel PD treatments.
Who is eligible to apply for this opportunity?
Eligibility is broad and includes public and private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses, and for-profit entities other than small businesses, along with certain other categories.
Are specific types of institutions explicitly included in the eligibility language?
Yes. The eligibility information explicitly includes institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions, among others.
Is cost sharing or matching required?
No cost sharing or matching requirement is listed for this opportunity, although the program still expects strong institutional support and demonstrated capacity.
What is the funding opportunity number (FOA) for this announcement?
The funding opportunity number is RFA NS 10 001.
When was this opportunity posted, and what are the key dates listed?
It was posted on October 6, 2009. The original and current closing date is December 10, 2009, and the archive date is January 10, 2010.
What CFDA number is associated with this program?
The CFDA number is 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).
What type of applicant is this opportunity best suited for, based on the description?
It is designed for institutions capable of running a coordinated, core-supported research enterprise that unites mechanistic discovery with preclinical and/or early clinical translation and can contribute to a national collaborative network focused on delivering new therapeutic options for people living with Parkinsons disease.
Browse more opportunities from the same category: Health
Next opportunity: Maintenance and downloading of acoustic receivers as part of cooperative salmon survival study
Previous opportunity: ROA 2009 A.3 Subsonic Rotary Wing Project (SSRW1)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NS 10 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NS 10 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| State and Regional Primary Care Association (PCA) Cooperative Agreements Apply for HRSA 10 115 Funding Number: HRSA 10 115 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| MBRS Research Initiative for Scientific Enhancement (RISE) (R25) Apply for PAR 10 004 Funding Number: PAR 10 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Water, Sanitation and Hygiene (WASH) Program in Liberia Apply for 669 10 001 Funding Number: 669 10 001 Agency: Liberia USAID Monrovia Category: Health Funding Amount: $10,500,000 |
| Cellular and Molecular Mechanisms of Arterial Stiffening and Its Relationship to Development of Hypertension (R01) Apply for RFA HL 10 027 Funding Number: RFA HL 10 027 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NHLBI Cardiovascular Outcomes Research Coordinating Unit (U01) Apply for RFA HL 10 018 Funding Number: RFA HL 10 018 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NHLBI Centers for Cardiovascular Outcomes Research (U01) Apply for RFA HL 10 008 Funding Number: RFA HL 10 008 Agency: National Institutes of Health Category: Health Funding Amount: $920,000 |
| Medical Liability Reform and Patient Safety Planning Grants (R21) Apply for RFA HS 10 022 Funding Number: RFA HS 10 022 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $300,000 |
| Medical Liability Reform and Patient Safety Demonstration Projects (R18) Apply for RFA HS 10 021 Funding Number: RFA HS 10 021 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $3,000,000 |
| Roadmap Transformative Research Projects Program (R01) Apply for RFA RM 09 022 Funding Number: RFA RM 09 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Case Ascertainment to Estimate the U.S. Prevalence of Fetal Alcohol Spectrum Disorders in Young Children (U01) Apply for RFA AA 10 005 Funding Number: RFA AA 10 005 Agency: National Institutes of Health Category: Health Funding Amount: $1,400,000 |
| Metagenomic Evaluation of Oral Polymicrobial Disease (R01) Apply for RFA DE 10 003 Funding Number: RFA DE 10 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grants to Expand Substance Abuse Treatment Capacity in Targeted Areas of Need Local Recovery Oriented Systems of Care Apply for TI 10 007 Funding Number: TI 10 007 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $400,000 |
| Population Based Birth Defects Surveillance and Utilization of Surveillance Data by Public Health Programs Apply for CDC RFA DD10 1001 Funding Number: CDC RFA DD10 1001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $220,000 |
| Preventing Unintentional Childhood Injuries (R21) Apply for RFA CE 10 001 Funding Number: RFA CE 10 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $175,000 |
| Public Health Conference Support Program Apply for CDC RFA DD10 1003 Funding Number: CDC RFA DD10 1003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Research Grants for Preventing Violence and Violence Related Injury (R01) Apply for RFA CE 10 005 Funding Number: RFA CE 10 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Research Priorities in Acute Injury Care (R01) Apply for RFA CE 10 003 Funding Number: RFA CE 10 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Development and Characterization of Animal Models for Aging Research (R01) Apply for PA 10 014 Funding Number: PA 10 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Unintentional Poisoning from Prescription Drug Overdoses in Adults (R21) Apply for RFA CE 10 002 Funding Number: RFA CE 10 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| Development and Characterization of Animal Models for Aging Research (R21) Apply for PA 10 015 Funding Number: PA 10 015 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NS 10 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.